GEMPHARMATECH CO., LTD. — Investor Relations & Filings
About GEMPHARMATECH CO., LTD.
GemPharmatech Co., Ltd. is a global biotechnology company specializing in the development and distribution of genetically engineered mouse models (GEMMs) for biomedical research. The company maintains one of the world's largest repositories of mouse strains, including knockout (KO), conditional knockout (cKO), and humanized models designed for oncology, immunology, and metabolic disease studies. Through its Knockout All Project, GemPharmatech aims to create KO and cKO strains for all protein-coding genes in the mouse genome. Beyond model production, the company provides comprehensive preclinical services such as efficacy testing, safety assessment, phenotyping, and customized gene editing using CRISPR/Cas9 technology. Serving pharmaceutical enterprises, biotechnology firms, and academic institutions, GemPharmatech supports drug discovery and fundamental life science research with high-throughput production capabilities and specialized germ-free mouse facilities.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 关于向不特定对象发行可转换公司债券摊薄即期回报与填补措施及相关主体承诺的公告 | 2023-08-04 | Chinese | |
| 独立董事关于第一届董事会第十九次会议相关事项的独立意见 | 2023-08-04 | Chinese | |
| 关于向不特定对象发行可转换公司债券预案披露的提示性公告 | 2023-08-04 | Chinese | |
| 向不特定对象发行可转换公司债券方案论证分析报告 | 2023-08-04 | Chinese | |
| 第一届监事会第十二次会议决议公告 | 2023-08-04 | Chinese | |
| 前次募集资金使用情况报告 | 2023-08-04 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2023
15 filings
| |||||
| 39533055 | 关于向不特定对象发行可转换公司债券摊薄即期回报与填补措施及相关主体承诺的公告 | 2023-08-04 | Chinese | ||
| 39533044 | 独立董事关于第一届董事会第十九次会议相关事项的独立意见 | 2023-08-04 | Chinese | ||
| 39533000 | 关于向不特定对象发行可转换公司债券预案披露的提示性公告 | 2023-08-04 | Chinese | ||
| 39532983 | 向不特定对象发行可转换公司债券方案论证分析报告 | 2023-08-04 | Chinese | ||
| 39532970 | 第一届监事会第十二次会议决议公告 | 2023-08-04 | Chinese | ||
| 39532941 | 前次募集资金使用情况报告 | 2023-08-04 | Chinese | ||
| 39532931 | 关于首次公开发行部分限售股上市流通的公告 | 2023-08-04 | Chinese | ||
| 39532917 | 向不特定对象发行可转换公司债券募集资金使用可行性分析报告 | 2023-08-04 | Chinese | ||
| 39532886 | 关于最近五年未被证券监管部门和证券交易所处罚或采取监管措施的公告 | 2023-08-04 | Chinese | ||
| 39532874 | 第一届董事会第十九次会议决议公告 | 2023-08-04 | Chinese | ||
| 39532834 | 关于公司未来三年（2023年-2025年）股东回报规划 | 2023-08-04 | Chinese | ||
| 39532822 | 中信证券股份有限公司关于江苏集萃药康生物科技股份有限公司股东向特定机构投资者询价转让股份的核查报告 | 2023-08-03 | Chinese | ||
| 39532815 | 股东询价转让结果报告书 | 2023-08-03 | Chinese | ||
| 39532807 | 关于变更签字会计师的公告 | 2023-08-02 | Chinese | ||
| 39532798 | 股东询价转让定价情况提示性公告 | 2023-07-31 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
GEMPHARMATECH CO., LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58096/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58096 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58096 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58096 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58096}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for GEMPHARMATECH CO., LTD. (id: 58096)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.